FNY Investment Advisers LLC Reduces Holdings in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT)

FNY Investment Advisers LLC lessened its holdings in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) by 45.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 39,219 shares of the company’s stock after selling 32,419 shares during the period. FNY Investment Advisers LLC owned 1.74% of Lixte Biotechnology worth $82,000 at the end of the most recent reporting period.

Lixte Biotechnology Price Performance

Shares of LIXT opened at $2.45 on Thursday. Lixte Biotechnology Holdings, Inc. has a 1-year low of $1.31 and a 1-year high of $4.40. The stock has a market cap of $5.51 million, a price-to-earnings ratio of -1.42 and a beta of -0.08. The firm has a 50 day simple moving average of $1.99 and a 200-day simple moving average of $2.01.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.